Pure Global
NCT06399692

REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

Weill Medical College of Cornell University·Phase 3·ClinicalTrials.gov·procedureNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Coronary Artery Disease
Drug/Device/Intervention
Coronary artery bypass grafting (CABG)
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Weill Medical College of Cornell University
Location
New York, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2024
End date
Jan 01, 2039
Enrollment
600 participants
Primary outcome

Hierarchical composite of all-cause death and time-averaged change from baseline in generic quality of life using the SF-12v2

Summary

This is a research study in women to compare the outcomes of two procedures that restore
 blood flow to the arteries of the heart. In one procedure the blockages are ballooned and
 then stented with a small wire mesh tube through a small incision in the wrist or the groin.
 The other procedure is an open-heart operation in which healthy blood vessels from inside the
 chest, leg, and/or forearm are used to bypass the blockages (like a detour). Outcomes will
 be measured by comparing survival and improvement in quality-of-life.

ICD-10 classifications
Cardiovascular disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart diseaseAbnormal findings on diagnostic imaging of heart and coronary circulationCoronary vasodilators, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06399692
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06399692 through Pure Global AI's free database. This Phase 3 trial is sponsored by Weill Medical College of Cornell University and is currently Not yet recruiting. The study focuses on Coronary Artery Disease. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.